Diverse Vaccine Platforms Safeguarding Against SARS-CoV-2 and Its Variants

Overview

Journal Expert Rev Vaccines

Date 2021 Oct 26

PMID 34697980

Citations 3

Authors

Bhaswati Chatterjee

Suman S Thakur

Affiliations

Soon will be listed here.

Abstract

Introduction: Appearances of SARS-CoV-2 variants have created havoc and additional challenges for the ongoing vaccination drive against pandemic COVID-19. Interestingly, several vaccine platforms are showing great potential to produce successful vaccines against SARS-CoV-2 and its variants. Billions of COVID-19 vaccine doses have been administered worldwide. Mix-and-Match COVID-19 vaccines involving the mixing of the same platform vaccines and also two different vaccine platforms may provide greater protection against SARS-CoV-2 and its variants. COVID-19 vaccines have become one of the most important tools to mitigate the ongoing pandemic COVID-19.

Areas Covered: We describe SARS-Cov-2 variants, their impact on the population, COVID-19 vaccines, diverse vaccine platforms, doses of vaccines, the efficacy of vaccines against SARS-CoV-2 and its variants, mitigation of the COVID-19 transmission- alternatives to vaccines.

Expert Opinion: Diverse vaccine platforms may safeguard against ongoing, deadly SARS-CoV-2 and its infectious variants. The efficacies of COVID-19 vaccines are significantly high after the administration of the second dose. Further, it protects individuals including vulnerable patients with co-morbidities from SARS-CoV-2 and its variants. The hospitalizations and deaths of the individuals may be prevented by COVID-19 vaccines.

Citing Articles

A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates.

Cui L, Li T, Lan M, Zhou M, Xue W, Zhang S iScience. 2024; 27(7):110208.

PMID: 39015149 PMC: 11251093. DOI: 10.1016/j.isci.2024.110208.

Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts Using Natural Language Processing, to Understand People's Perspectives Regarding COVID-19 Booster Vaccine Shots in India: Crucial to Expanding Vaccination Coverage.

Sv P, Lorenz J, Ittamalla R, Dhama K, Chakraborty C, Kumar D Vaccines (Basel). 2022; 10(11).

PMID: 36423024 PMC: 9692646. DOI: 10.3390/vaccines10111929.

Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2.

Wei H, Zhang C, Du X, Zhang Z Talanta. 2022; 251:123813.

PMID: 35952504 PMC: 9356646. DOI: 10.1016/j.talanta.2022.123813.

References

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah M . Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871):276-280. DOI: 10.1038/s41586-021-03777-9. View

Zhu F, Li Y, Guan X, Hou L, Wang W, Li J . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240):1845-1854. PMC: 7255193. DOI: 10.1016/S0140-6736(20)31208-3. View

Emary K, Golubchik T, Aley P, Ariani C, Angus B, Bibi S . Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021; 397(10282):1351-1362. PMC: 8009612. DOI: 10.1016/S0140-6736(21)00628-0. View

Collier D, De Marco A, Ferreira I, Meng B, Datir R, Walls A . Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021; 593(7857):136-141. PMC: 7616976. DOI: 10.1038/s41586-021-03412-7. View

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

Hotez P, Bottazzi M . Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020; 14(7):e0008548. PMC: 7390283. DOI: 10.1371/journal.pntd.0008548. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Zang J, Zhu Y, Zhou Y, Gu C, Yi Y, Wang S . Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. Cell Discov. 2021; 7(1):71. PMC: 8372230. DOI: 10.1038/s41421-021-00315-9. View

10.

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

11.

Zhang L, Jackson C, Mou H, Ojha A, Peng H, Quinlan B . SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. PMC: 7693302. DOI: 10.1038/s41467-020-19808-4. View

12.

Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K . Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592(7852):116-121. PMC: 8158177. DOI: 10.1038/s41586-020-2895-3. View

13.

de Abajo F, Rodriguez-Martin S, Lerma V, Mejia-Abril G, Aguilar M, Garcia-Luque A . Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020; 395(10238):1705-1714. PMC: 7255214. DOI: 10.1016/S0140-6736(20)31030-8. View

14.

Shim E . Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea. Int J Environ Res Public Health. 2021; 18(14). PMC: 8306637. DOI: 10.3390/ijerph18147578. View

15.

Kunal S, Sakthivel P, Gupta N, Ish P . Mix and match COVID-19 vaccines: potential benefit and perspective from India. Postgrad Med J. 2023; 98(e2):e99-e101. DOI: 10.1136/postgradmedj-2021-140648. View

16.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

17.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

18.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

19.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

20.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View